MiniMed Flex Puts MiniMed on the Front Foot as a Stand-Alone

MiniMed Group's first full quarter as a stand-alone public company was anything but quiet. “Organic growth was 16% and ahead of expectations” — Que Dallara, Chief Executive Officer · 2026-09-01, with the U.S. accelerating to 13% revenue growth (from 1.5% in Q4) and international markets up 16.9% on a comparable basis. The engine is the MiniMed Flex insulin pump system, launched with the Simplera sensor in late June. It is doing exactly what management designed it to do: expanding into new patients, driving competitive conversions, and lifting the installed base. U.S. new pumps sold rose over 20% year‐over‐year, and new prescribers grew 24%.

Pipeline Cadence Accelerates

What really changes the investment debate is the pipeline, which is slipping left. MiniMed Flex received CE Mark approval well ahead of year‐end, Fit was submitted to the FDA ahead of fro the summer‐next year launch target, Vivera's U.S. pivotal trial is fully enrolled, and the next‑generation extended wear sensor received IDE approval. As Que Dallara put it, “We are building a complete platform for insulin-taking patients, smart pen, durable pump, patch pump, one algorithm, one app, one ecosystem.” — Que Dallara, Chief Executive Officer · 2026-09-01 The patch pump (Fit) is particularly important: it brings a 300‑unit reservoir and up to 7 days of wear to the fastest‑growing segment of the pump market, features that are directly tailored to Type 2 patients who make up roughly 40% of new U.S. starts. Meanwhile, Vivera, the fully closed‑loop algorithm, has completed enrollment and could remove even the need for meal announcements.

We do not view Vivera as the next version of an algorithm. We view it as a category-defining platform that brings fully closed-loop therapy to both Type 1 and Type 2 patients at scale, further expanding the gap between MiniMed and the competition.

Financial Reality Check

The GAAP picture remains distorted by one‑time separation costs. Free cash flow swung to a ‑$234M use of cash in the quarter, but management highlighted that “Excluding that, we generated $21 million of positive free cash flow” — Chad Spooner, Chief Financial Officer · 2026-09-01 — a normalization they expect to become more visible as TSA exits roll off. The company finished the quarter with $207M of cash, no debt, and an undrawn $500M revolver, providing ample cushion. Guidance was raised to ~10.5% organic revenue growth for fiscal 2027 while adjusted EBITDA margin guidance held at ~16%, supported by better‐than‑expected Simplera yields and rising operating leverage. The trailing free cash flow (less SBC) figure of -$234M versus a +$4M peak in Q2 2025 highlights the temporary drag of the separation.

Positioning for the Long Run

What distinguishes this report is the way the pieces are converging. The company is not just launching isolated products; it is building an ecosystem that spans smart pens, durable pumps, patch pumps, and next‑generation sensors. The installed base is expanding, and with CGM attachment rates already at 69% and climbing, the recurring revenue stream becomes more durable. Internationally, countries like France and the U.K. are showing double‑digit pump sales growth as new sensors and flexible form factors roll out. Management is explicit that the opportunity is underpenetrated: automated insulin delivery is still early in adoption, especially for Type 2. The company's ability to move the calendar to the left on multiple front‐end programs — Flex CE Mark, Fit 510(k) submission, Vivera enrollment, and IDE for the extended‑wear sensor — gives it a genuine competitive edge. As Que said, “We are building for the next quarter, the next year and the next decade.” For a company that just emerged from a carved‑out cost structure, this quarter demonstrates that the operating model can generate both growth and improving margins, and that the product pipeline can sustain it.